Location of Repository

Preliminary Study of 99m Tc-HL91 on a Tumor Mouse Model

By Guang-uei Hung, Yih-chyang Weng, Wan-yu Lin, Shyh-jen Wang, Chien-chung Hsia, Shiaw-pyng Wey, Hsin-ell Wang, Cheng-hsien Lin, Lie-hang Shen and Gann Ting

Abstract

Background: Many malignant tumors are characterized by perfusion heterogeneity due to its proliferation more rapid than the vascularity, which results in tumor regions that are acutely or chronically hypoxia. 99m Tc-HL91 is an amine oxime core radioligand that has shown oxygen dependent passive in vivo and in vitro binding with higher binding under hypoxic conditions than under non-hypoxic conditions. This study evaluated the domestic preparation of 99m Tc-HL91 for its feasibility as a tumor imaging agent, and compared the results with 201 Tl-TlCl ( 201 Tl). Methods: The lyophilized kits of HL91 and 201 Tl-TlCl were produced by INER. Following reconstitution of the kit with 99m Tc-pertechnetate, 99m Tc-HL91 was injected intravenously into C3H mice bearing KHT sarcoma xenografts. Whole-body scans were performed at 1 h, 1.5 h and 2 h post-injection. The ratios of tumor-to-normal tissue background (T/N) were measured. After imaging study, the mice were sacrificed and underwent autoradiography. Parallel studies with 201 Tl were performed for comparison. Results: There was increased uptake of 99m Tc-HL91 at tumor regions. The T/N ratios of 99m Tc-HL91 measured at 1 h, 1.5 h and 2 h were 2.986, 2.351 and 1.872, respectively. The images of 201 Tl showed similar distribu

Topics: Key words, 99m Tc-HL91, tumor, hypoxic Ann Nucl Med Sci 2002, 15, 85-91
Year: 2014
OAI identifier: oai:CiteSeerX.psu:10.1.1.412.6203
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://citeseerx.ist.psu.edu/v... (external link)
  • http://www.snm.org.tw/revista2... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.